



TEXAS TECH UNIVERSITY HEALTH SCIENCES CENTER School of Medicine Cancer Center

Cell Line Data Sheet for CHLA-122

Disease:	Neuroblastoma
Phase of Therapy:	Diagnosis
Treatment:	None
Disease Stage:	4
Gender:	Female
Age at diagnosis:	24 months
Race:	N/A
Age at sample collection:	N/A
Source of Culture:	Bone Marrow
Primary Tumor Site:	N/A
Date Established:	November 1992
MYCN Patient:	Amplified
MYCN Cell line:	N/A
THmRNA:	Expressed
p53 status:	Functional
Telomere Mechanism:	N/A
ALK:	WT
RNAseq:	N/A
WES:	N/A
	Please see Protocols section at https://www.cccells.org/protocols.php
Growth Conditions:	5% CO ₂ , 20% O ₂ , 37.0°C
Media Formulation:	Please see Protocols section at https://www.cccells.org/protocols.php
Media Formulation:	Cells are grown in a base medium of Iscove's Modified Dulbecco's Medium plus the following
	supplements (to a final concentration): 20% Fetal Bovine Serum, 4mM L-Glutamine, 1X ITS (5
Develing Times	μg/mL insulin, 5 μg/mL transferrin, 5 ng/mL selenous acid)
Doubling Time:	72 hours
Growth Properties:	Suspended, grow mostly in tight clumps
STR Profile:	May be obtained at https://strdb.cccells.org/
Notes:	COGcell.org has a post-treatment cell line available from this same patient (CHLA-136). The
110163.	repository has a matching EBV lymphoblastoid cell line – COG-V-450. The repository has a
	matching fibroblast line – COG-FB-451.

All COG Repository cell lines are antibiotic-free, mycoplasma-free, and cryopreserved in 50% FBS / 7.5% DMSO. Each vial label contains the cell line name, passage number, total viable cell count (usually 5-10e6), the overall cell viability, and date frozen. All cell lines are validated with original patient sample by STR analysis.







Cell Line Data Sheet for CHLA-122

Cell Line Name: CHLA-122 References:

> Keshelava N, Zuo JJ, Chen P, Waidyaratine SN, Luna MC, Gomer CJ, Triche TJ, Reynolds C P: Loss of p53 function confers high-level multi-drug resistance in neuroblastoma cell lines. *Cancer Res.* 61:6185-6193, 2001. PubMed ID: <u>11507071</u>

https://cancerres.aacrjournals.org/content/61/16/6185.long

2. Keshelava N, Davicioni E, Wan Z, Ji L, Sposto R, Triche TJ, Reynolds CP. Histone Deacetylase 1 Gene Expression and Sensitization of Multidrug-Resistant Neuroblastoma Cell Lines to Cytotoxic Agents by Depsipeptide. *J Natl Cancer I*. 99: 1107-19, 2007.

PubMed ID: <u>17623797</u> <u>https://academic.oup.com/jnci/article/99/14/1107/938992</u>

3. Harned TM, Kalous O, Neuwelt A, Loera J, Ji L, Iovine P, Sposto R, Neuwelt EA, Reynolds CP: Sodium Thiosulfate (STS) administered six hours after cisplatin does not compromise anti-neuroblastoma activity. *Clin Cancer Res.* 14:533-540, 2008. PubMed ID: 18223229

https://clincancerres.aacrjournals.org/content/14/2/533.long

4. Kang MH, Smith MA, Morton CL, Keshlava N, Houghton PJ, Reynolds CP. National Cancer Institute Pediatric Preclinical Testing Program: Model Description for In Vitro Cytotoxicity Testing. *Pediat Blood Cancer*. 56: 239-249, 2011. PubMed ID: 20922763

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3005554/

(www.PPTPinvitro.org)

Childhood Cancer Repository Powered by Alex's Lemonade Stand COG resource Laboratory www.cccells.org

2/3





Cell Line Data Sheet for CHLA-122


CHILDREN'S

ONCOLOGY GROUP

Cell Line Name:


CHLA-122

(10x magnification)




(10x magnification)

(20x magnification)



(20x magnification)



Childhood Cancer Repository Powered by Alex's Lemonade Stand COG resource Laboratory www.cccells.org